Oxford PharmaGenesis expertise in rare diseases was showcased in the April edition of PharmaTimes. The article ‘Time To Think Rare’ quoted Commercial Director Dr Richard White (http://tinyurl.com/hhk3xme) alongside other well-known figures in the rare diseases arena, including Alastair Kent (Director of the Genetic Alliance and Chair of Rare Disease UK) and Kay Parkinson (Chief Executive of the Cambridge Rare Disease Network).
“Rare genetic disorders pose unique challenges for patients and their families,” said Chris Winchester, Managing Director of Oxford PharmaGenesis. “At Oxford PharmaGenesis, we have seen how charities and patient groups, working together with clinicians, researchers and the biopharmaceutical industry, can transform the lives of patients with rare diseases.”
Oxford PharmaGenesis has a strong heritage in the rare diseases arena, with more than 15 years of experience in providing expert guidance to various stakeholders seeking to improve standards of care for patients with rare diseases. Click here for further information on our specialist Rare and Orphan Diseases Practice.
